Arbutus Biopharma Corp Deferred Revenue (Non-Current)
Arbutus Biopharma Corp (ABUS) had Deferred Revenue (Non-Current) of $0 as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2026-03-23
- 2012-12-31: Deferred Revenue, Noncurrent 722.45K CAD; Deferred Revenue, Noncurrent as first filed 718.78K CAD.
- 2011-12-31: Deferred Revenue, Noncurrent 1.69M CAD.
- 2010-12-31: Deferred Revenue, Noncurrent 2.16M CAD.
CAD
| Period end | Deferred Revenue, Noncurrent | Deferred Revenue, Noncurrent as first filed |
|---|---|---|
| 2012-12-31 | 722.45K CAD 10-K · filed 2014-03-28 | 718.78K CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 1.69M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 2.16M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.86M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.86M 10-K · filed 2026-03-23 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 |
| 2023-03-31 | $3.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $6.00M 10-K · filed 2024-03-05 |
| 2022-09-30 | $10.59M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $10.84M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $15.59M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2017-06-30 | $4.13M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $4.78M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-03 |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-04 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-04 |
| 2015-12-31 | $213.00K 10-K · filed 2017-03-22 |
| 2015-09-30 | $6.89M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $8.04M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $7.90M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $9.94M 10-K · filed 2016-03-09 |
| 2014-09-30 | $10.07M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $10.51M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $10.00M 10-Q · filed 2014-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |